Olgu Sunumu
BibTex RIS Kaynak Göster

EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT

Yıl 2018, Cilt: 5 Sayı: 2, 43 - 46, 01.06.2018

Öz

Aims: Tuberous sclerosis complex is a genetic disorder characterized by mutations in Tuberous Sclerosis Complex 1 (* 605284) or Tuberous Sclerosis Complex 2 (* 191092) genes. PALB2 (* 610355) gene has long been known to be associated with increased breast and pancreatic cancer risk. Its association with risk of stomach and lung cancers has also been established recently. In this case report, it is aimed to present a case of a 24-year-old female patient, who has been diagnosed with both novel mosaic Tuberous Sclerosis Complex 2 pathogenic variation and pathogenic PALB2 variation at the same time.

Case Report: A 24-year-old female patient was admitted to Trakya University Genetic Diseases Center with suspected tuberous sclerosis complex. Her primary complaints were a continuous headache and fatigue. She had no history of convulsion and seizure. There were bilateral facial angiofibromas around her nose. When genomic DNA was isolated, both novel mosaic Tuberous Sclerosis Complex 2 pathogenic variation and pathogenic PALB2 variation were observed.

Conclusion: This case report shows that in cancer predisposing syndromes, Next-generation sequencing is a powerful technique to portrait a detailed genetic profile of patient, investigating for any mosaicism or other risk alleles. 

Kaynakça

  • 1. Nellist M, Brouwer RW, Kockx CE et al. Targeted Next generation sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet 2015;16:10.
  • 2. Avgeris S, Fostira F, Vagena A et al. Mutational analysis of TSC1 and TSC2 genes in tuberous sclerosis complex patients from Greece. Sci Rep 2017;7(1):16697.
  • 3. Lee JEA, Li N, Rowley SM et al. Molecular analysis of PALB2-associated breast cancers. J Pathol 2018;245(1):53-60.
  • 4. Bleuyard JY, Butler RM, Esashi F. Perturbation of PALB2 function by the T413S mutation found in small cell lung cancer. Wellcome Open Res 2017;2:110.
  • 5. Serratì S, De Summa S, Pilato B et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets and Ther 2016;9:7355–65.
  • 6. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-24.
  • 7. Blackburn HL, Schroeder B, Turner C et al. Management of incidental findings in the era of Next-generation sequencing. Curr Genomics 2015;16(3):159-74.
Yıl 2018, Cilt: 5 Sayı: 2, 43 - 46, 01.06.2018

Öz

Kaynakça

  • 1. Nellist M, Brouwer RW, Kockx CE et al. Targeted Next generation sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet 2015;16:10.
  • 2. Avgeris S, Fostira F, Vagena A et al. Mutational analysis of TSC1 and TSC2 genes in tuberous sclerosis complex patients from Greece. Sci Rep 2017;7(1):16697.
  • 3. Lee JEA, Li N, Rowley SM et al. Molecular analysis of PALB2-associated breast cancers. J Pathol 2018;245(1):53-60.
  • 4. Bleuyard JY, Butler RM, Esashi F. Perturbation of PALB2 function by the T413S mutation found in small cell lung cancer. Wellcome Open Res 2017;2:110.
  • 5. Serratì S, De Summa S, Pilato B et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets and Ther 2016;9:7355–65.
  • 6. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-24.
  • 7. Blackburn HL, Schroeder B, Turner C et al. Management of incidental findings in the era of Next-generation sequencing. Curr Genomics 2015;16(3):159-74.
Toplam 7 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Olgu Sunumu
Yazarlar

Hilal Sena Çifcibaşı

Elçin Gülbal Bu kişi benim

Ayşenur Erdoğan Bu kişi benim

Ayşenur Demirci Bu kişi benim

Selma Demir

Yayımlanma Tarihi 1 Haziran 2018
Gönderilme Tarihi 23 Nisan 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 5 Sayı: 2

Kaynak Göster

APA Çifcibaşı, H. S., Gülbal, E., Erdoğan, A., Demirci, A., vd. (2018). EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT. Turkish Medical Student Journal, 5(2), 43-46.
AMA Çifcibaşı HS, Gülbal E, Erdoğan A, Demirci A, Demir S. EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT. TMSJ. Haziran 2018;5(2):43-46.
Chicago Çifcibaşı, Hilal Sena, Elçin Gülbal, Ayşenur Erdoğan, Ayşenur Demirci, ve Selma Demir. “EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT”. Turkish Medical Student Journal 5, sy. 2 (Haziran 2018): 43-46.
EndNote Çifcibaşı HS, Gülbal E, Erdoğan A, Demirci A, Demir S (01 Haziran 2018) EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT. Turkish Medical Student Journal 5 2 43–46.
IEEE H. S. Çifcibaşı, E. Gülbal, A. Erdoğan, A. Demirci, ve S. Demir, “EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT”, TMSJ, c. 5, sy. 2, ss. 43–46, 2018.
ISNAD Çifcibaşı, Hilal Sena vd. “EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT”. Turkish Medical Student Journal 5/2 (Haziran 2018), 43-46.
JAMA Çifcibaşı HS, Gülbal E, Erdoğan A, Demirci A, Demir S. EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT. TMSJ. 2018;5:43–46.
MLA Çifcibaşı, Hilal Sena vd. “EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT”. Turkish Medical Student Journal, c. 5, sy. 2, 2018, ss. 43-46.
Vancouver Çifcibaşı HS, Gülbal E, Erdoğan A, Demirci A, Demir S. EFFECTIVE USE OF NEXT GENERATION SEQUENCING FOR GENETIC DIAGNOSIS OF A PATIENT WITH A MOSAIC TSC2 VARIANT. TMSJ. 2018;5(2):43-6.